Author Question: Protecting internal validity A) is a minor concern in experimentation. B) cannot be achieve with ... (Read 39 times)

jlmhmf

  • Hero Member
  • *****
  • Posts: 552
Protecting internal validity
 
  A) is a minor concern in experimentation.
  B) cannot be achieve with fewer than 100 participants.
  C) is the primary purpose of experimentation.
  D) is achieved whenever sample size is equal in all the groups.

Question 2

Protecting against threats to internal validity is
 
  A) a major aim of experimental design.
  B) of maximum concern in naturalistic research.
  C) achieved when sample size is equal in each group.
  D) the main purpose of differential design.



ryansturges

  • Sr. Member
  • ****
  • Posts: 338
Answer to Question 1

Answer: C

Answer to Question 2

Answer: A



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Glaucoma is a leading cause of blindness. As of yet, there is no cure. Everyone is at risk, and there may be no warning signs. It is six to eight times more common in African Americans than in whites. The best and most effective way to detect glaucoma is to receive a dilated eye examination.

Did you know?

The National Institutes of Health have supported research into acupuncture. This has shown that acupuncture significantly reduced pain associated with osteoarthritis of the knee, when used as a complement to conventional therapies.

Did you know?

As many as 28% of hospitalized patients requiring mechanical ventilators to help them breathe (for more than 48 hours) will develop ventilator-associated pneumonia. Current therapy involves intravenous antibiotics, but new antibiotics that can be inhaled (and more directly treat the infection) are being developed.

Did you know?

Opium has influenced much of the world's most popular literature. The following authors were all opium users, of varying degrees: Lewis Carroll, Charles, Dickens, Arthur Conan Doyle, and Oscar Wilde.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library